Comparative Pharmacology
Head-to-head clinical analysis: AMBODRYL versus ATARAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBODRYL versus ATARAX.
AMBODRYL vs ATARAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine (H1-receptor antagonist) with anticholinergic and sedative properties.
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed, up to a maximum of 80 mg/day.
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life 12-15 hours in adults; prolonged to 20-30 hours in hepatic impairment.
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
Primarily renal (70-80% as metabolites, 20-30% unchanged); biliary/fecal excretion accounts for 15-20%.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Category C
Category C
Antihistamine
Antihistamine